<DOC>
	<DOCNO>NCT00239915</DOCNO>
	<brief_summary>This research study investigational drug , Pagoclone , treatment persistent developmental stuttering ( PDS ) , include frequent repetition prolongation sound syllable word , frequent hesitation pause disrupt flow speech . Pagoclone investigational drug , approve United States Food Drug Administration .</brief_summary>
	<brief_title>Safety Efficacy Study Investigational Drug Pagoclone , Treatment Persistent Developmental Stuttering ( PDS )</brief_title>
	<detailed_description />
	<mesh_term>Stuttering</mesh_term>
	<criteria>PDS define DSMIVTR criterion Symptoms start age 8 Total overall score 1836 SSI3 English speaking , 8th grade education Able understand cooperate study requirement assistance Not pregnant breastfeed Able provide consent No diagnose CNS/Mental health disorder last 6 month No use psychotropic medication medication stutter within 4 week prior screen No use nonmedicinal stuttering treatment 5 month prior study No use illicit drug opiates kind</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>